MDT vs TNDM: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

MDT is the larger of the two ($129.16B market cap): the incumbent the market prices for continued execution (15.76x forward earnings, beta 0.57). TNDM is the smaller challenger ($1.28B), actually pricier on forward earnings (136.71x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

MDT vs TNDM: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricMDTTNDMWhat it tells you
Market cap$129.16B$1.28BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E15.76136.71Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.571.60Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range84% of range35% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.579.45How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: MDT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how MDT and TNDM affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MDT and TNDM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MDT and TNDM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Medtronic (MDT) do?

Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans three main areas after October 2026: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), and Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform). Its former Diabetes unit (insulin pumps and continuous glucose monitoring) was carved out as MiniMed, which listed on Nasdaq under MMED; on October 15, 2026 Medtronic exchanged its remaining 252.8 million MiniMed shares for Medtronic shares in an exchange offer that was 5.4 times subscribed, so it no longer owns any of MiniMed. The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics, with trailing revenue of about $37.5 billion as of October 2026.

Full MDT guide

What does Tandem Diabetes Care (TNDM) do?

Tandem Diabetes Care designs, makes, and sells insulin pumps for people with diabetes. Its flagship products are the t:slim X2 pump and the much smaller Tandem Mobi system, both running Control-IQ+ automated insulin delivery software that reads data from a continuous glucose monitor (CGM) and automatically adjusts insulin dosing. The business works on a razor-and-blade model: Tandem earns an up-front sale when a customer adopts a pump, then recurring revenue from the disposable cartridges, infusion sets, and other supplies that customer buys for years afterward. Pumps integrate with third-party CGMs from Dexcom (G6/G7) and Abbott (FreeStyle Libre), which Tandem does not make itself.

Full TNDM guide

MDT vs TNDM: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • MDT drivers: Diversified device portfolio; Innovation pipeline and new product cycles.
  • TNDM drivers: Recurring supplies and a growing installed base; Tandem Mobi and Control-IQ+ product cycle.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. For TNDM, competition is the central risk: Insulet's tubeless Omnipod 5 is the fastest-growing system in the market, Medtronic remains a large incumbent, and newer entrants like Beta Bionics' iLet and Sequel's twiist add pressure, all of which can squeeze Tandem's pricing and pump share.

MDT or TNDM: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MDT if you believe its drivers more; TNDM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MDT and TNDM guides.

MDT vs TNDM: the full fundamentals

MDT. At about $95 on October 16, 2026, Medtronic trades near 15 times forward earnings, a moderate multiple next to faster-growing medtech peers, while the GAAP trailing P/E of about 23x includes acquisition amortization. The 25 analysts tracked by Yahoo Finance hold a mean target near $104. The next report, expected around November 17, 2026, will be the first read on the company after the MiniMed exit, with consensus at about $1.33 of EPS on $9.5 billion of revenue.

TNDM. Tandem is best read as a growth medtech rather than a mature, profitable company, so investors tend to watch pump shipments, installed-base growth, gross margin, and the path to positive adjusted EBITDA rather than a simple P/E ratio. At about 1.1 times trailing sales and roughly $1.2 billion in market value, the shares price in modest expectations for a business that analysts see moving to small profits in 2027; the forward P/E near 107 mostly reflects how thin those projected earnings still are. Third-quarter results on November 5, 2026 come with a consensus of about $265.9 million in revenue and a loss of $0.24 per share.

Headline figures (approximate, October 2026): MDT shows revenue (ttm) ~$37.5 billion, up ~14% year over year in the July 2026 quarter, margins ~65% gross, ~19% operating, ~14% net, net income (ttm) ~$5.2 billion, eps ~$4.07 GAAP trailing; ~$6.41 forward estimate; TNDM shows revenue (ttm) ~$1.04 billion, revenue growth (latest quarter) ~6% year over year (Q2 2026: ~$254.6M), gross margin (ttm) ~56%; operating margin ~-5%, net income (ttm) ~-$63 million; EPS ~-$0.91.

The bottom line: MDT vs TNDM

MDT and TNDM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MDT and TNDM exposure against your real portfolio. It is not an investment adviser.

Wondering how MDT or TNDM fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Medtronic

Ask Walnut's AI anything about MDT and see how it fits what you own.

FAQ

What is the difference between MDT and TNDM?

+

Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Tandem Diabetes Care designs, makes, and sells insulin pumps for people with diabetes. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is MDT or TNDM the better stock?

+

Neither is universally better. MDT is the larger incumbent; TNDM is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, MDT or TNDM?

+

On forward P/E (as of November 2026), MDT trades at 15.76x and TNDM at 136.71x, so MDT is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both MDT and TNDM?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of MDT vs TNDM?

+

MDT: Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. The Hugo robotic platform faces an entrenched Intuitive Surgical. The MiniMed separation removes diabetes but adds near-term noise: reported results, guidance and comparisons will shift as the unit leaves the numbers, and analysts expect EPS of about $1.33 for the quarter ending October 2026, slightly below the year-earlier level. Device companies face reimbursement pressure, hospital budget constraints, FDA approval and recall risk, and litigation exposure. A large international footprint brings currency headwinds, and debt stood near $28 billion against about $8.8 billion of cash as of October 2026. The stock is roughly flat over the past year despite faster sales growth. New-product execution, pipeline timing, and the ability to sustain organic growth remain the key swing factors for the investment case. TNDM: Competition is the central risk: Insulet's tubeless Omnipod 5 is the fastest-growing system in the market, Medtronic remains a large incumbent, and newer entrants like Beta Bionics' iLet and Sequel's twiist add pressure, all of which can squeeze Tandem's pricing and pump share. GLP-1 weight-loss drugs are a structural unknown that management has acknowledged may have weighed on the broader insulin-therapy market since 2023, though the long-term effect on pump demand is unclear. Tandem still posts GAAP net losses (about $63 million over the trailing twelve months, after about $204.7 million in 2025), burned roughly $44 million of free cash flow over that period, and carries about $739 million of debt against about $456 million of cash. It must execute its PayGo pharmacy-channel transition without losing customers, while reimbursement decisions and product execution on Mobi and new integrations all carry uncertainty. Analysts have trimmed targets too: Truist cut its price target to $28 from $31 in September 2026 while keeping a Buy rating.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell MDT or TNDM; figures are approximate and dated (as of November 2026). Verify current data before investing.